Advertisement
RARE vs SBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a Hold and SBIO is a Hold.
RARE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RARE turned positive on September 22, 2026. Looking at past instances where RARE's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RARE's RSI Indicator exited the oversold zone, 26 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on RARE as a result. In 69 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +10.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in 220 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 152 of 226 cases where RARE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
RARE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.302) is normal, around the industry mean (3.043). P/E Ratio (-2.684) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (1.809) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SBIO's Indicator enters downward trend
The Aroon Indicator for SBIO entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator formed such a pattern. In 191 of the 212 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SBIO as a result. In 75 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SBIO's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on October 20, 2026. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in 47 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Following a +9.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in 279 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
SBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
RARE | ||
|---|---|---|
OUTLOOK RATING 1..100 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | |
P/E GROWTH RATING 1..100 | 11 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| RARE | SBIO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 72% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 87% |
| MACD ODDS (%) | 3 days ago 85% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 72% | 1 day ago 89% |
| Advances ODDS (%) | 5 days ago 79% | 5 days ago 88% |
| Declines ODDS (%) | 11 days ago 81% | 1 day ago 88% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RARE’s FA Score shows that 2 FA rating(s) are green while .
- RARE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RARE’s TA Score shows that 5 TA indicator(s) are bullish.
- RARE’s TA Score: 5 bullish, 3 bearish.
Price Growth
RARE (@Biotechnology) experienced а +7.63% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
RARE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RARE and
Correlation & Price change
A.I.dvisor indicates that over the last year, RARE has been loosely correlated with MREO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then MREO could also see price increases.
| Ticker / NAME | Correlation To RARE | 1D Price Change % | ||
|---|---|---|---|---|
| RARE | 100% | -1.88% | ||
| MREO - RARE | 58% Loosely correlated | -1.98% | ||
| VCYT - RARE | 46% Loosely correlated | +4.11% | ||
| APVO - RARE | 39% Loosely correlated | -0.62% | ||
| MLTX - RARE | 37% Loosely correlated | -3.97% | ||
| AMRN - RARE | 36% Loosely correlated | +1.64% | ||
More | ||||
SBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, SBIO has been loosely correlated with RARE. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SBIO jumps, then RARE could also see price increases.
| Ticker / NAME | Correlation To SBIO | 1D Price Change % | ||
|---|---|---|---|---|
| SBIO | 100% | -2.14% | ||
| RARE - SBIO | 64% Loosely correlated | -1.88% | ||
| FATE - SBIO | 59% Loosely correlated | +0.96% | ||
| ROIV - SBIO | 58% Loosely correlated | -2.56% | ||
| EDIT - SBIO | 58% Loosely correlated | -3.61% | ||
| RCUS - SBIO | 57% Loosely correlated | -4.24% | ||
More | ||||